Treatment of Type2 Diabetes
-
SGLT2 Inhibitors Proving Powerful for T2D; Important for Younger Patients?
We spoke with Naveed Sattar, MD, PhD with the University of Glasgow, Scotland about the Credence Study and its…
Read More » -
Cardiologist Education Key to Adoption of Advanced T2D Drugs
We corresponded with Felona Gunawan, MD (bio) from the endocrinology department at the Yale School of Medicine and Yale-New Haven…
Read More » -
Is Muscle Mass the Fountain of Youth?
We spoke with Angelique (Angie) Brellenthin, a postdoctoral researcher in kinesiology at Iowa State University and co-author of a new…
Read More » -
ADA Updates Standards to include Vascepa for T2D Cardio Care
For 2019, the ADA updated Section 10 of its Standards of Care based on the published results of the REDUCE-IT study,…
Read More » -
A1c Not Reliable in Diagnosing T2D
“Based on our findings, A1c should not be solely used to determine the prevalence of diabetes,” said lead researcher Maria…
Read More » -
Basal Insulin Management is not easy. This new tool could help
Lower Fasting Glucose When people with Type 2 Diabetes start basal insulin treatment, the goal is to reach a lower…
Read More » -
Prescription EPA Substantially Lowers Cardiovascular Risk in People with T2D
We spoke with Robert Busch, MD, an endocrinologist at Albany Medical Center about the REDUCE-IT cardiovascular risk reduction clinical trial…
Read More » -
iGlucose Is Simple, Affordable and Connected
We spoke with Cliff McIntosh, CEO of Smart Meter, which he has led since 2014, following success in other start-ups…
Read More » -
Hygieia Rewriting Advanced T2D Care!
We spoke with Eran Bashan, CEO, Co-founder, and Chairman of Hygieia based in Livonia, Michigan. See https://hygieia.com/ App is Small…
Read More » -
Fine Tuning An A1C Strategy
The drug-specific and patient-specific factors described in our earlier coverage become a bit nuanced here.
Read More »
